Last updated: February 15, 2026
What is the current market status for NDC 29300-0130?
NDC 29300-0130 is a formulation of Epogen (epoetin alfa), a biosimilar or branded erythropoiesis-stimulating agent (ESA) used primarily in anemia management associated with chronic kidney disease (CKD), chemotherapy, and HIV treatment. The medication is marketed by Amgen, with potential biosimilar competitors entering or competing in this space.
What is the current market landscape for erythropoiesis-stimulating agents?
The global ESAs market was valued at approximately $4.5 billion in 2022, with growth projections reaching $6 billion by 2028, registering a CAGR of 5.5% (source: Grand View Research). The U.S. remains the largest market, driven by the prevalence of CKD and the adoption of advanced biosimilar versions.
The competitive landscape contains several top players:
- Amgen (Epogen, Procrit, Retacrit biosimilar)
- Pfizer (Retacrit biosimilar)
- Dr. Reddy’s (epoetin alfa)
The market share concentration favors Amgen, which holds a dominant position with its patent protections ending around 2013 but continues to influence market dynamics through patent litigations and biosimilar launches.
What are the key regulatory and patent considerations?
- Patent Status: Amgen's patents for Epogen expired in multiple jurisdictions by 2013, opening pathways for biosimilar competition.
- Biosimilar Approvals: The FDA has approved biosimilars like Retacrit (by Pfizer and others), which rapidly gained market share due to lower price points.
- Pricing Policies: Medicare, Medicaid, and private insurers heavily influence pricing strategies, with biosimilar entries pressuring providers to reduce reimbursement rates.
How is pricing structured for NDC 29300-0130?
- Brand Price: List prices for Epogen formulations range from $150 to $200 per dose (source: Red Book, 2022).
- Biosimilar Price: Biosimilars are priced approximately 15% to 30% lower; for example, Retacrit is listed at around $125 per dose.
- Reimbursement: CMS reimbursement rates typically align with average sales price (ASP). Biosimilars benefit from reduced ASPs in line with negotiated discounts and tender contracts.
What are the recent price trends and projections?
- 2022 Observation: Prices of branded Epogen stabilized around $150-$200 per dose due to patent and supply constraints.
- 2023 Trends: Biosimilar prices dropped by 10-15% as market penetration increased. Large hospital systems transitioned to biosimilars, forcing further price reductions.
- Price Projections (2024-2028):
| Year |
Estimated Average Price Per Dose |
Notes |
| 2024 |
$130 - $150 |
Continued biosimilar adoption, cost pressures |
| 2025 |
$125 - $145 |
Market saturation, price competition increases |
| 2026 |
$120 - $140 |
Potential new biosimilar entrants |
| 2027 |
$115 - $130 |
Market stabilization, additional biosimilar options |
| 2028 |
$110 - $125 |
Long-term price plateau, leaner procurement processes |
What are the key drivers and risks influencing the market?
Drivers:
- Growing CKD prevalence worldwide; the U.S. alone reports over 37 million people with CKD.
- Increased adoption of biosimilars reducing treatment costs.
- Regulatory encouragement for biosimilar use, which is incentivized through policies like the FDA's Biosimilar Action Plan.
Risks:
- Patent litigations delaying biosimilar market entries.
- Shifts in treatment guidelines away from ESAs due to safety concerns (e.g., cardiovascular risks associated with higher hemoglobin targets).
- Adoption barriers in certain segments, such as hospital formularies lagging behind biosimilar entry.
What are the market entry and competitive strategy considerations?
Healthcare providers and payers prioritize cost savings, favoring biosimilars. New entrants should focus on:
- Demonstrating equivalent efficacy and safety.
- Establishing strong pricing strategies aligned with payer negotiations.
- Engaging in early formulary reviews to secure preferred status.
Conclusions and implications for price projections
While branded Epogen remains available, biosimilar competition exerts downward price pressure. Market maturity and regulatory factors contribute to stabilization of prices around $110-$125 per dose by 2028.
Key Takeaways
- NDC 29300-0130 (Epogen) faces substantial biosimilar competition in the U.S. and global markets.
- Prices for the drug are declining, with projections indicating a further reduction to approximately $110-$125 per dose by 2028.
- The market is driven by high CKD prevalence, biosimilar adoption, and policy shifts favoring cost-effective treatments.
- Patent expirations and regulatory approvals are critical to market dynamics.
- Market entry strategies should focus on demonstrating biosimilar efficacy and securing formulary access to capitalize on cost savings.
FAQs
1. What are the main factors influencing pricing for NDC 29300-0130?
Regulatory approvals, patent status, biosimilar competition, and payer reimbursement policies significantly impact prices.
2. How does biosimilar competition affect the original product’s price?
Biosimilar entry generally reduces the brand's price through increased market competition, with reductions ranging from 15% to 30%.
3. What is the expected timeline for biosimilar penetration in the erythropoietic agent market?
Biosimilars are expected to capture 30%-50% of the market share within 3 to 5 years post-approval, depending on formulary acceptance and policy support.
4. What are the primary safety considerations affecting ESA utilization?
Risks include cardiovascular events at higher hemoglobin targets, prompting cautious dosing and sometimes limiting ESA use.
5. How can manufacturers or investors leverage this data?
By noting declining price trends and biosimilar entry, stakeholders can optimize market entry timing, pricing strategies, and contract negotiations.
References
- Grand View Research. "Erythropoiesis-Stimulating Agents Market Size, Share & Trends Analysis Report." 2022.
- Red Book. "Drug Pricing Data." 2022.
- U.S. Food and Drug Administration. "Biosimilar Product Information." 2023.
- Centers for Medicare & Medicaid Services. "ASP Medicare Part B Drug Payment Amounts." 2023.
- IQVIA. "Market Insights: Biosimilars." 2023.
